Harnessing the Human Immune System

The immune system is nature’s most powerful weapon against disease. Trellis Bioscience is an NIH and venture-funded biotechnology company that leverages its proprietary CellSpot™ technology to derive rare, naturally optimized antibodies from healthy donor blood against infectious diseases and cancer.

Due to their human origin, our therapeutics are safer and more effective than alternatives.

Our Technology

Using our proprietary CellSpot Platform we discover the most effective antibodies in healthy donor blood for therapeutic use in non-immune patients

Our Therapeutic Candidates

Trellis has derived five human monoclonal antibody (mAbs) therapeutics against bacterial, viral and cancer indications. All candidates are in preclinical development and will reach Phase I clinical trials by 2019.

Biofilm Tile HCMV Tile Pan-influenza Tile RSV Tile Cancer Tile

In vivo and in vitro experimental data show our antibodies possess superior binding affinity, broad-spectrum capabilities, and efficacy compared to alternative therapies

Biofilm is a leading cause of antibiotic resistance. This Scanning Electron Microscropy photograph at 4000X magnification shows our antibody, TRL1068, disrupting biofilm in Pseudomonas aeruginosa, a multi-drug resistant, gram-negative bacteria species.

Antibiotic Resistant

Antibiotic Susceptible

OUR COMPANY


We are business leaders and scientists passionate about developing human antibody therapies to various diseases.

Our team offers diverse academic and operational expertise, covering all stages of drug development:

1) Discovery

2) Preclinical Development

3) Clinical Trials

4) Commercialization

© 2010-2019 TRELLIS BIOSCIENCE. ALL RIGHTS RESERVED.